These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Suppressed Vascular Leakage and Myocardial Edema Improve Outcome From Myocardial Infarction. Li X; Redfors B; Sáinz-Jaspeado M; Shi S; Martinsson P; Padhan N; Scharin Täng M; Borén J; Levin M; Claesson-Welsh L Front Physiol; 2020; 11():763. PubMed ID: 32733273 [TBL] [Abstract][Full Text] [Related]
6. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1. Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795 [TBL] [Abstract][Full Text] [Related]
7. Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Bouleti C; Mathivet T; Coqueran B; Serfaty JM; Lesage M; Berland E; Ardidie-Robouant C; Kauffenstein G; Henrion D; Lapergue B; Mazighi M; Duyckaerts C; Thurston G; Valenzuela DM; Murphy AJ; Yancopoulos GD; Monnot C; Margaill I; Germain S Eur Heart J; 2013 Dec; 34(47):3657-68. PubMed ID: 23674618 [TBL] [Abstract][Full Text] [Related]
8. ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway. Xu J; Wu F; Zhu Y; Wu T; Cao T; Gao W; Liu M; Qian W; Feng G; Xi X; Hou S Cancer Cell Int; 2024 Feb; 24(1):54. PubMed ID: 38311733 [TBL] [Abstract][Full Text] [Related]
10. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Galaup A; Gomez E; Souktani R; Durand M; Cazes A; Monnot C; Teillon J; Le Jan S; Bouleti C; Briois G; Philippe J; Pons S; Martin V; Assaly R; Bonnin P; Ratajczak P; Janin A; Thurston G; Valenzuela DM; Murphy AJ; Yancopoulos GD; Tissier R; Berdeaux A; Ghaleh B; Germain S Circulation; 2012 Jan; 125(1):140-9. PubMed ID: 22086875 [TBL] [Abstract][Full Text] [Related]
11. ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway. Zhu X; Guo X; Wu S; Wei L Lung; 2016 Aug; 194(4):637-46. PubMed ID: 27166634 [TBL] [Abstract][Full Text] [Related]
12. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway. Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659 [TBL] [Abstract][Full Text] [Related]
13. Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma. Abdulkhalek S; Geen OD; Brodhagen L; Haxho F; Alghamdi F; Allison S; Simmons DJ; O'Shea LK; Neufeld RJ; Szewczuk MR Clin Transl Med; 2014 Dec; 3(1):28. PubMed ID: 26932374 [TBL] [Abstract][Full Text] [Related]
14. FBXW7 inhibits invasion, migration and angiogenesis in ovarian cancer cells by suppressing VEGF expression through inactivation of β-catenin signaling. Zhong L; Pan Y; Shen J Exp Ther Med; 2021 May; 21(5):514. PubMed ID: 33791023 [TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-like 4-Induced 3D Capillary Morphogenesis Correlates to Stabilization of Endothelial Adherens Junctions and Restriction of VEGF-Induced Sprouting. Liabotis A; Ardidie-Robouant C; Mailly P; Besbes S; Gutierrez C; Atlas Y; Muller L; Germain S; Monnot C Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203415 [TBL] [Abstract][Full Text] [Related]
16. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. Zhang Q; Lu S; Li T; Yu L; Zhang Y; Zeng H; Qian X; Bi J; Lin Y J Exp Clin Cancer Res; 2019 Apr; 38(1):173. PubMed ID: 31023337 [TBL] [Abstract][Full Text] [Related]
17. ANGPTL4 plays a paradoxical role in gastric cancer through the LGALS7 and Hedgehog pathways. Xie J; Li Y; Zeng T; Fan T; Shan H; Shi G; Zhou W; Zou J; Lei X Sci Rep; 2024 Oct; 14(1):23173. PubMed ID: 39369030 [TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer. Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321 [TBL] [Abstract][Full Text] [Related]
19. The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features. Nieminen T; Toivanen PI; Rintanen N; Heikura T; Jauhiainen S; Airenne KJ; Alitalo K; Marjomäki V; Ylä-Herttuala S Biochim Biophys Acta; 2014 Jan; 1840(1):454-63. PubMed ID: 24112971 [TBL] [Abstract][Full Text] [Related]
20. Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2. Sadremomtaz A; Kobarfard F; Mansouri K; Mirzanejad L; Asghari SM J Recept Signal Transduct Res; 2018; 38(5-6):432-441. PubMed ID: 30929546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]